| 摘要: |
| 原发性肝癌是我国最常见的恶性肿瘤之一，病死率高，其主要病理类型为肝细胞癌。大多肝细胞癌患者在初诊时已是晚期，5年生存率低于16%，实现肝癌的早发现和早诊断有助于改善患者的预后。血液检测具有微创、客观、经济、可重复和可动态监测的优点，可用于肝细胞癌高危人群的筛查和辅助诊断。本文回顾了已有报道的肝细胞癌血液检测指标，分为血清中可直接检出的标志物、细胞外囊泡中的标志物及循环肿瘤细胞中的标志物3类，阐述其优势及局限性，并对未来肝癌早期筛查的血液学检测新策略进行展望。 |
| 关键词: 肝肿瘤 肝细胞癌 肿瘤生物标志物 筛查 早期诊断 |
| DOI：10.16781/j.CN31-2187/R.20210661 |
| 投稿时间：2021-07-01修订日期：2022-01-06 |
| 基金项目: |
|
| Blood test indicators for hepatocellular carcinoma: research progress |
| FAN Zhe-cai1,2,YANG Zhao3* |
(1. Department of Medical Transcription, National Center for Liver Cancer, Naval Medical University (Second Military Medical University), Shanghai 201805, China;
2. International Cooperation Laboratory on Signal Transduction, The Third Affiliated Hospital of Naval Medical University (Second Military Medical University), Shanghai 200438, China;
3. Department of Hepatic Surgery (Ⅱ), The Third Affiliated Hospital of Naval Medical University (Second Military Medical University), Shanghai 200438, China
*Corresponding author) |
| Abstract: |
| Primary liver cancer is one of the most common malignant tumors in China, with high incidence and mortality, and the main pathological type is hepatocellular carcinoma (HCC). Most patients with HCC are already at the advanced stages at the first diagnosis, with the 5-year survival rate being less than 16%. Early detection and early diagnosis of liver cancer can help improve the prognosis of patients. Blood testing is commonly used to screen patients with high risks of liver cancer because it is minimally invasive, objective, economical, repeatable and easy to monitored. This article summarized 3 types of reported indicators for blood screening of liver cancer:biomarkers that could be directly detected in the serum, biomarkers in the cargoes transferred by extracellular vesicles, and biomarkers in circulating tumor cells. The advantages and limitations of each category were discussed. We also provided perspectives for the promising strategies of blood testing for HCC screening and diagnosis in future. |
| Key words: liver neoplasms hepatocellular carcinoma tumor biomarkers screening early diagnosis |
